{
  "id": 17779824,
  "title": "Fresenius Taps China’s WuXi to Expand Biosimilar Drug Portfolio",
  "url": "https://urgent.news/2026/11/02/fresenius-taps-chinas-wuxi-to-expand-biosimilar-drug-portfolio",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-02T09:59:41.000Z",
  "source": {
    "name": "Bloomberg",
    "slug": "bloomberg",
    "url": "https://www.bloomberg.com/news/articles/2026-11-02/fresenius-taps-china-s-wuxi-to-expand-biosimilar-drug-portfolio"
  },
  "original_language": "en",
  "account": null,
  "summary": "Fresenius SE agreed to partner with Chinese contract drug developer WuXi Biologics on biosimilar candidates that could reach the market in the next decade, potentially more than doubling its current portfolio.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}